Author response: A Drug Repurposing Approach Reveals Targetable Epigenetic Pathways in Plasmodium vivax Hypnozoites

Steven P. Maher, Malina A. Bakowski, Amélie Vantaux, Erika L. Flannery, Chiara Andolina, Manoj Kumar Gupta, Yevgeniya Antonova‐Koch, M. Argomaniz, Monica Cabrera-Mora, Brice Campo, A. T. Chao, Arnab K. Chatterjee, Wenjie Cheng, E. Chuenchob, Caitlin Cooper, Karissa E. Cottier, Mary R. Galinski, Anke Harupa-Chung, Hye Young Ji, Sean B. Joseph, Thomas Lenz, Stefano Lonardi, J. Matheson, Sebastian A. Mikolajczak, T. Moeller, A Orban, Vivian Padín-Irizarry, K. Pan, Julie Péneau, Jacques Prudhomme, Camille Roesch, Anthony A. Ruberto, Svapna Sabnis, Celia L. Saney, Jetsumon Sattabongkot, Saleh Sereshki, Sangrawee Suriyakan, Ratawan Ubalee, Yin Wang, Praphan Wasisakun, Junqi Yin, Jean Popovici, Case W. McNamara, Chester J. Joyner, François Nosten, Benoît Witkowski, Karine G. Le Roch, Dennis E. KyleOpenalex Unknown 2024 · DOI · OpenAlex

TL;DR

Researchers have identified that epigenetic pathways—the chemical "switches" that turn genes on and off—are critical for the survival of dormant malaria parasites (Plasmodium vivax) hiding in the liver. By screening thousands of existing drugs, the team discovered that repurposed compounds and specific epigenetic inhibitors can wake up or kill these "sleeping" parasites, offering a potential path toward a radical cure for malaria.

What Problem Does This Paper Address?

While Plasmodium falciparum is the most famous malaria parasite, Plasmodium vivax is the most widespread and arguably the most difficult to eliminate. Its secret weapon is the hypnozoite: a dormant stage where the parasite "sleeps" inside human liver cells for months or even years. These sleepers eventually wake up, causing a relapse of the disease and fueling further transmission.

Currently, only one class of drugs (8-aminoquinolines like Primaquine) can kill hypnozoites. However, these drugs are dangerous for people with a common genetic condition (G6PD deficiency) and cannot be given to pregnant women. We desperately need new, safer drugs that can clear these dormant reservoirs—a goal known as a "radical cure."

Methods

The authors employed a multi-pronged chemical biology approach:

  • High-Throughput Screening: They used a specialized in vitro platform where primary human hepatocytes (liver cells) were infected with P. vivax sporozoites. They screened the ReFRAME library, a collection of ~12,000 compounds that are already FDA-approved or in clinical trials.
  • Epigenetic Library Screen: Following initial hits, they screened a targeted library of 773 epigenetic inhibitors.
  • Genomic Mapping: To prove the parasite actually uses epigenetic markers, they used bisulfite sequencing and immunofluorescence to map DNA methylation (specifically 5-methylcytosine or 5mC) across the parasite's genome.
  • Synergy Testing: They used isobologram analysis to see if combining different drugs (like the antihypertensive cadralazine and the DNA methyltransferase inhibitor 5-azacytidine) produced a greater-than-additive effect.

Datasets

  • ReFRAME Library: 12,823 compounds (developmental, approved, or discontinued drugs).
  • Targetmol Epigenetic Library: 773 compounds targeting various epigenetic enzymes.
  • Genomic Data: Bisulfite sequencing reads from P. vivax and P. cynomolgi (a closely related monkey malaria) sporozoites, now available in the NCBI Sequence Read Archive (PRJNA925570).
  • Transcriptomic Data: Previously published P. vivax liver-stage RNA-seq data used for correlation with methylation patterns.

Key Insights and Ideas

  • The Epigenetic Cloak: The study provides some of the strongest evidence to date that Plasmodium parasites utilize DNA methylation to regulate their life cycle. They found that methylation levels in the promoter regions of genes inversely correlate with gene expression—meaning the parasite uses these chemical tags to keep certain genes "silenced" during dormancy.
  • Repurposing Antihypertensives: Surprisingly, two old blood pressure medications, hydralazine and cadralazine, were found to kill hypnozoites. These drugs are known to inhibit DNA methyltransferases in humans, suggesting they might be hitting a similar target in the parasite.
  • Targeting the "Power Plant": The team identified MMV019721, an inhibitor of acetyl-CoA synthetase (ACS), as a potent hypnozonticidal agent. ACS is vital because it provides the raw materials for histone acetylation, another key epigenetic modification.
  • Species Sensitivity Gaps: A major "aha" moment (and a cautionary tale) was that cadralazine worked against human P. vivax but failed against the monkey model P. cynomolgi both in vitro and in vivo. This highlights that while monkey models are the "gold standard," they aren't perfect mirrors of human infection.

Key Results

  • Cadralazine Potency: Identified as a top hit with a pEC50 of 6.33 (roughly 470 nM) and near 100% maximal inhibition of hypnozoites.
  • Epigenetic Hits: Identified 11 compounds targeting five different epigenetic mechanisms (including HDAC and histone methyltransferase inhibitors) with selective activity against hypnozoites.
  • Methylation Levels: Bisulfite sequencing revealed an average 5mC level of 0.49% in P. vivax sporozoites, with signals concentrated in coding genes and promoters.
  • Synergy: Combining cadralazine with 5-azacytidine increased potency by ~2-fold, supporting the hypothesis that these drugs act on the same epigenetic pathway.

Limitations and Future Work

  • Mechanism of Action: While the evidence strongly points to epigenetic targeting, the authors acknowledge they haven't yet "caught the smoking gun"—direct biochemical proof that cadralazine binds to a specific P. vivax protein.
  • Host vs. Parasite: It remains difficult to definitively prove whether these drugs act directly on the parasite or by modifying the host liver cell environment to make it inhospitable for the "sleeper."
  • Animal Models: The failure of cadralazine in the rhesus macaque model suggests that future drug discovery must balance in vitro human cell data with animal models carefully.
  • Next Steps: The authors suggest that the chemical probes identified here should be used with single-cell technology to further deconstruct the molecular triggers that cause a parasite to wake up.

Summary updated

Abstract

Radical cure of Plasmodium vivax malaria must include elimination of quiescent ‘hypnozoite’ forms in the liver; however, the only FDA-approved treatments are contraindicated in many vulnerable populations. To identify new drugs and drug targets for hypnozoites, we screened the Repurposing, Focused Rescue, and Accelerated Medchem (ReFRAME) library and a collection of epigenetic inhibitors against P. vivax liver stages. From both libraries, we identified inhibitors targeting epigenetics pathways as selectively active against P. vivax and P. cynomolgi hypnozoites. These include DNA methyltransferase (DNMT) inhibitors as well as several inhibitors targeting histone post-translational modifications. Immunofluorescence staining of Plasmodium liver forms showed strong nuclear 5-methylcystosine signal, indicating liver stage parasite DNA is methylated. Using bisulfite sequencing, we mapped genomic DNA methylation in sporozoites, revealing DNA methylation signals in most coding genes. We also demonstrated that methylation level in proximal promoter regions as well as in the first exon of the genes may affect, at least partially, gene expression in P. vivax. The importance of selective inhibitors targeting epigenetic features on hypnozoites was validated using MMV019721, an acetyl-CoA synthetase inhibitor that affects histone acetylation and was previously reported as active against P. falciparum blood stages. In summary, our data indicate that several epigenetic mechanisms are likely modulating hypnozoite formation or persistence and provide an avenue for the discovery and development of improved radical cure antimalarials.Drug repurposing screens reveal several epigenetic inhibitors as active against P. vivax hypnozoites demonstrating that epigenetic pathways play a central role in hypnozoite quiescence.
BibTeX
@inproceedings{maher2024author,
  author = {Steven P. Maher and Malina A. Bakowski and Amélie Vantaux and Erika L. Flannery and Chiara Andolina and Manoj Kumar Gupta and Yevgeniya Antonova‐Koch and M. Argomaniz and Monica Cabrera-Mora and Brice Campo and A. T. Chao and Arnab K. Chatterjee and Wenjie Cheng and E. Chuenchob and Caitlin Cooper and Karissa E. Cottier and Mary R. Galinski and Anke Harupa-Chung and Hye Young Ji and Sean B. Joseph and Thomas Lenz and Stefano Lonardi and J. Matheson and Sebastian A. Mikolajczak and T. Moeller and A Orban and Vivian Padín-Irizarry and K. Pan and Julie Péneau and Jacques Prudhomme and Camille Roesch and Anthony A. Ruberto and Svapna Sabnis and Celia L. Saney and Jetsumon Sattabongkot and Saleh Sereshki and Sangrawee Suriyakan and Ratawan Ubalee and Yin Wang and Praphan Wasisakun and Junqi Yin and Jean Popovici and Case W. McNamara and Chester J. Joyner and François Nosten and Benoît Witkowski and Karine G. Le Roch and Dennis E. Kyle},
  title = {{Author response: A Drug Repurposing Approach Reveals Targetable Epigenetic Pathways in Plasmodium vivax Hypnozoites}},
  booktitle = {Openalex Unknown},
  year = {2024},
  doi = {10.7554/elife.98221.1.sa4},
}

Loading related content...

Figure